We will achieve this by:
Innovating the design of clinical trial and molecular pathology platforms that anticipate the future of precision medicine;
Establishing early detection and risk stratification for personalised cancer risk management;
Improving the quality of life and survival of cancer patients through nationally co-ordinated, collaborative, research-led, evidence-based care;
Growing the health economy through greater engagement with industry.